Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease

被引:55
作者
Chetelat, Gael [1 ,2 ,3 ,4 ]
Ossenkoppele, Rik [5 ,6 ,7 ,8 ]
Villemagne, Victor L. [9 ,10 ]
Perrotin, Audrey [1 ,2 ,3 ,4 ]
Landeau, Brigitte [1 ,2 ,3 ,4 ]
Mezenge, Florence [1 ,2 ,3 ,4 ]
Jagust, William J. [11 ,12 ]
Dore, Vincent [9 ,10 ,13 ]
Miller, Bruce L. [8 ]
Egret, Stephanie [1 ,2 ,3 ,4 ]
Seeley, William W. [8 ]
van der Flier, Wiesje M. [7 ,14 ]
La Joie, Renaud [1 ,2 ,3 ,4 ]
Ames, David [15 ,16 ]
van Berckel, Bart N. M. [7 ]
Scheltens, Philip [5 ,6 ]
Barkhof, Frederik [7 ]
Rowe, Christopher C. [9 ,10 ]
Masters, Colin L. [17 ]
de La Sayette, Vincent [1 ,2 ,3 ,4 ,18 ]
Bouwman, Femke [5 ,6 ]
Rabinovici, Gil D. [8 ,11 ,12 ]
机构
[1] INSERM, U1077, F-14074 Caen, France
[2] Univ Caen Basse Normandie, UMR S1077, F-14074 Caen, France
[3] Ecole Prat Hautes Etud, UMR S1077, F-14074 Caen, France
[4] CHU Caen, U1077, F-14000 Caen, France
[5] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Neurosci Campus Amsterdam, NL-1081 HZ Amsterdam, Netherlands
[6] Vrije Univ Amsterdam, Alzheimer Ctr, NL-1081 HZ Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol & Nucl Med, NL-1081 HZ Amsterdam, Netherlands
[8] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94720 USA
[9] Austin Hlth, Dept Nucl Med, Melbourne, Vic 3084, Australia
[10] Austin Hlth, Ctr PET, Melbourne, Vic 3084, Australia
[11] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA
[12] Lawrence Berkeley Natl Lab, Berkeley, CA USA
[13] CSIRO, Hlth & Biosecur Flagship, Brisbane, Qld 4006, Australia
[14] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, NL-1081 HZ Amsterdam, Netherlands
[15] Univ Melbourne, Dept Psychiat, St Vincents Hlth, Acad Unit Psychiat Old Age, Kew, Vic 3101, Australia
[16] Natl Ageing Res Inst, Parkville, Vic 3052, Australia
[17] Mental Hlth, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic 3010, Australia
[18] CHU Caen, Serv Neurol, F-14000 Caen, France
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
amyloid; PET; MRI; Alzheimer's disease; retrosplenial posterior cingulate; PITTSBURGH COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; CEREBROSPINAL-FLUID; NATIONAL INSTITUTE; A-BETA; PIB PET; FDG-PET; DEMENTIA; BIOMARKERS; DIAGNOSIS;
D O I
10.1093/brain/aww159
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
About 15% of patients clinically diagnosed with Alzheimer's disease do not show high tracer retention on amyloid positon emission tomography imaging. The present study investigates clinical and demographic features, patterns of brain atrophy and hypometabolism and longitudinal clinical trajectories of these patients. Forty amyloid-negative patients carrying a pre-scan diagnosis of Alzheimer's disease dementia from four centres were included (11/29 females/males; mean age = 67 +/- 9). Detailed clinical histories, including the clinical diagnoses before and after the amyloid scan and at follow-up, were collected. Patients were classified according to their pre-scan clinical phenotype as amnestic (memory predominant), non-amnestic (predominant language, visuospatial or frontal symptoms), or non-specific (diffuse cognitive deficits). Demographic, clinical, neuropsychological, magnetic resonance imaging and F-18-fluorodeoxyglucose positon emission tomography data were compared to 27 amyloid-positive typical Alzheimer's disease cases (14/13 females/males; mean age = 71 +/- 10) and 29 amyloid-negative controls (15/14 females/males; mean age = 69 +/- 12) matched for age, gender and education. There were 21 amnestic, 12 non-amnestic, and seven non-specific amyloid-negative Alzheimer's disease cases. Amyloid-negative subgroups did not differ in age, gender or education. After the amyloid scan, clinicians altered the diagnosis in 68% of amyloid-negative patients including 48% of amnestic versus 94% of non-amnestic and non-specific cases. Amnestic amyloid-negative cases were most often reclassified as frontotemporal dementia, non-amnestic as frontotemporal dementia or corticobasal degeneration, and non-specific as dementia with Lewy bodies or unknown diagnosis. The longer-term clinical follow-up was consistent with the post-scan diagnosis in most cases (90%), including in amnestic amyloid-negative cases whose post-positon emission tomography diagnosis remained Alzheimer's disease. While the non-amnestic and non-specific amyloid-negative cases usually showed patterns of atrophy and hypometabolism suggestive of another degenerative disorder, the amnestic amyloid-negative cases had subtle atrophy and hypometabolism, restricted to the retrosplenial/posterior cingulate cortex. Patients with a negative amyloid positon emission tomography scan following an initial clinical diagnosis of Alzheimer's disease have heterogeneous clinical presentations and neuroimaging profiles; a majority showed a clinical progression that was consistent with a neurodegenerative condition. In contrast, in the subgroup of amnestic amyloid-negative cases, the clinical presentation and follow-up usually remained consistent with Alzheimer's disease. An alternative diagnosis was not made in about half of the amnestic amyloid-negative cases, highlighting the need for a clinical framework and terminology to define these patients, who may have underlying limbic-predominant, non-amyloid-related pathologies.
引用
收藏
页码:2528 / 2539
页数:12
相关论文
共 55 条
  • [1] Focal cortical presentations of Alzheimer's disease
    Alladi, S.
    Xuereb, J.
    Bak, T.
    Nestor, P.
    Knibb, J.
    Patterson, K.
    Hodges, J. R.
    [J]. BRAIN, 2007, 130 : 2636 - 2645
  • [2] Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010
    Beach, Thomas G.
    Monsell, Sarah E.
    Phillips, Leslie E.
    Kukull, Walter
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2012, 71 (04) : 266 - 273
  • [3] Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    Blennow, Kaj
    Hampel, Harald
    Weiner, Michael
    Zetterberg, Henrik
    [J]. NATURE REVIEWS NEUROLOGY, 2010, 6 (03) : 131 - 144
  • [4] Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease
    Cairns, Nigel J.
    Ikonomovic, Milos D.
    Benzinger, Tammie
    Storandt, Martha
    Fagan, Anne M.
    Shah, Aarti R.
    Reinwald, Lisa Taylor
    Carter, Deborah
    Felton, Angela
    Holtzman, David M.
    Mintun, Mark A.
    Klunk, William E.
    Morris, John C.
    [J]. ARCHIVES OF NEUROLOGY, 2009, 66 (12) : 1557 - 1562
  • [5] Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimers disease
    Chetelat, G.
    Desgranges, B.
    Landeau, B.
    Mezenge, F.
    Poline, J. B.
    de la Sayette, V.
    Viader, F.
    Eustache, F.
    Baron, J. -C.
    [J]. BRAIN, 2008, 131 : 60 - 71
  • [6] Primary age-related tauopathy (PART): a common pathology associated with human aging
    Crary, John F.
    Trojanowski, John Q.
    Schneider, Julie A.
    Abisambra, Jose F.
    Abner, Erin L.
    Alafuzoff, Irina
    Arnold, Steven E.
    Attems, Johannes
    Beach, Thomas G.
    Bigio, Eileen H.
    Cairns, Nigel J.
    Dickson, Dennis W.
    Gearing, Marla
    Grinberg, Lea T.
    Hof, Patrick R.
    Hyman, Bradley T.
    Jellinger, Kurt
    Jicha, Gregory A.
    Kovacs, Gabor G.
    Knopman, David S.
    Kofler, Julia
    Kukull, Walter A.
    Mackenzie, Ian R.
    Masliah, Eliezer
    McKee, Ann
    Montine, Thomas J.
    Murray, Melissa E.
    Neltner, Janna H.
    Santa-Maria, Ismael
    Seeley, William W.
    Serrano-Pozo, Alberto
    Shelanski, Michael L.
    Stein, Thor
    Takao, Masaki
    Thal, Dietmar R.
    Toledo, Jonathan B.
    Troncoso, Juan C.
    Vonsattel, Jean Paul
    White, Charles L., III
    Wisniewski, Thomas
    Woltjer, Randall L.
    Yamada, Masahito
    Nelson, Peter T.
    [J]. ACTA NEUROPATHOLOGICA, 2014, 128 (06) : 755 - 766
  • [7] Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia.: A PET study
    Diehl, J
    Grimmer, T
    Drzezga, A
    Riemenschneider, M
    Förstl, H
    Kurz, A
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 (08) : 1051 - 1056
  • [8] Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study
    Doraiswamy, P. Murali
    Sperling, Reisa A.
    Coleman, R. Edward
    Johnson, Keith A.
    Reiman, Eric M.
    Davis, Mat D.
    Grundman, Michael
    Sabbagh, Marwan N.
    Sadowsky, Carl H.
    Fleisher, Adam S.
    Carpenter, Alan
    Clark, Christopher M.
    Joshi, Abhinay D.
    Mintun, Mark A.
    Skovronsky, Daniel M.
    Pontecorvo, Michael J.
    [J]. NEUROLOGY, 2012, 79 (16) : 1636 - 1644
  • [9] Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Hampel, Harald
    Molinuevo, Jose Luis
    Blennow, Kaj
    Dekosky, Steven T.
    Gauthier, Serge
    Selkoe, Dennis
    Bateman, Randall
    Cappa, Stefano
    Crutch, Sebastian
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Fox, Nick C.
    Galasko, Douglas
    Habert, Marie-Odile
    Jicha, Gregory A.
    Nordberg, Agneta
    Pasquier, Florence
    Rabinovici, Gil
    Robert, Philippe
    Rowe, Christopher
    Salloway, Stephen
    Sarazin, Marie
    Epelbaum, Stephane
    de Souza, Leonardo C.
    Vellas, Bruno
    Visser, Pieter J.
    Schneider, Lon
    Stern, Yaakov
    Scheltens, Philip
    Cummings, Jeffrey L.
    [J]. LANCET NEUROLOGY, 2014, 13 (06) : 614 - 629
  • [10] The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
    Duits, Flora H.
    Teunissen, Charlotte E.
    Bouwman, Femke H.
    Visser, Pieter-Jelle
    Mattsson, Niklas
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Minthon, Lennart
    Andreasen, Niels
    Marcusson, Jan
    Wallin, Anders
    Rikkert, Marcel Olde
    Tsolaki, Magda
    Parnetti, Lucilla
    Herukka, Sanna-Kaisa
    Hampel, Harald
    De Leon, Mony J.
    Schroeder, Johannes
    Aarsland, Dag
    Blankenstein, Marinus A.
    Scheltens, Philip
    van der Flier, Wiesje M.
    [J]. ALZHEIMERS & DEMENTIA, 2014, 10 (06) : 713 - 723